
Merck & Co., Inc.
MRKAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 2, 2026 | Cantor Fitzgerald | Carter Gould | $155.00(+5%) | $147.94 | StreetInsider |
| Oct 30, 2026 | Guggenheim | Vamil Divan | $171.00(+17%) | $146.33 | StreetInsider |
| Oct 30, 2026 | KeyBanc | $165.00(+13%) | $146.33 | StreetInsider | |
| Oct 26, 2026 | Barclays | $180.00(+24%) | $145.27 | TheFly | |
| Oct 22, 2026 | Wells Fargo | $165.00(+12%) | $147.24 | TheFly | |
| Oct 19, 2026 | Goldman Sachs | $155.00(+6%) | $146.26 | TheFly | |
| Oct 12, 2026 | RBC Capital | Trung Huynh | $145.00(-0%) | $145.60 | StreetInsider |
| Oct 8, 2026 | Cantor Fitzgerald | Carter Gould | $145.00(+2%) | $142.79 | StreetInsider |
| Sep 29, 2026 | Scotiabank | $180.00(+22%) | $147.15 | TheFly | |
| Sep 11, 2026 | Berenberg Bank | Luisa Hector | $137.00(-5%) | $144.71 | StreetInsider |
| Sep 10, 2026 | HSBC | $172.00(+17%) | $147.60 | TheFly | |
| Sep 9, 2026 | Leerink Partners | $161.00(+8%) | $148.49 | TheFly | |
| Sep 8, 2026 | Guggenheim | Vamil Divan | $170.00(+13%) | $150.34 | StreetInsider |
| Sep 4, 2026 | Wells Fargo | $170.00(+12%) | $152.34 | TheFly | |
| Aug 25, 2026 | Argus Research | Jasper Hellweg | $170.00(+11%) | $153.61 | TheFly |
| Aug 25, 2026 | Wolfe Research | Alexandria Hammond | $180.00(+19%) | $150.69 | TheFly |
| Aug 21, 2026 | Goldman Sachs | $160.00(+7%) | $149.25 | TheFly | |
| Aug 20, 2026 | BMO Capital | $170.00(+14%) | $149.65 | TheFly | |
| Aug 20, 2026 | UBS | $175.00(+15%) | $152.22 | TheFly | |
| Aug 20, 2026 | RBC Capital | $150.00(-1%) | $152.22 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Freedom Broker | maintain | Hold | Nov 2, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Nov 2, 2026 |
| Guggenheim | maintain | Buy | Oct 30, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 30, 2026 |
| JP Morgan | maintain | Overweight | Oct 30, 2026 |
| Barclays | maintain | Overweight | Oct 26, 2026 |
| Citigroup | maintain | Neutral | Oct 12, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 12, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Oct 8, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 7, 2026 |
| JP Morgan | maintain | Overweight | Oct 5, 2026 |
| Scotiabank | maintain | Sector Outperform | Sep 29, 2026 |
| HSBC | maintain | Buy | Sep 10, 2026 |
| Leerink Partners | maintain | Outperform | Sep 9, 2026 |
| Guggenheim | maintain | Buy | Sep 8, 2026 |
| Wells Fargo | maintain | Overweight | Sep 4, 2026 |
| Wolfe Research | maintain | Outperform | Aug 25, 2026 |
| Argus Research | maintain | Buy | Aug 25, 2026 |
| Goldman Sachs | maintain | Buy | Aug 21, 2026 |
| Morgan Stanley | upgrade | Equal Weight →Overweight | Aug 20, 2026 |
| BMO Capital | maintain | Outperform | Aug 20, 2026 |
| UBS | maintain | Buy | Aug 20, 2026 |
| RBC Capital | downgrade | Outperform →Sector Perform | Aug 20, 2026 |
| Daiwa Capital | upgrade | Neutral →Outperform | Aug 12, 2026 |
| Argus Research | maintain | Buy | Aug 11, 2026 |
Earnings History
Next report: Feb 2, 2027 · EPS est. $1.78| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 29, 2026 | $2.49 | $2.09 | $18.09B | $17.33B |
| Aug 4, 2026 | $-0.13 | $-0.27 | $16.61B | $16.37B |
| Apr 30, 2026 | $-1.28 | $-1.47 | $16.29B | $15.85B |
| Feb 3, 2026 | $2.04 | $2.01 | $16.40B | $16.20B |
| Oct 30, 2025 | $2.58 | $2.36 | $17.28B | $16.98B |
| Jul 29, 2025 | $2.13 | $2.03 | $15.81B | $15.86B |
| Apr 24, 2025 | $2.22 | $2.13 | $15.53B | $15.34B |
| Feb 4, 2025 | $1.72 | $1.85 | $15.62B | $15.48B |
News
Two men start the same one-minute cancer shot on the same day, yet their Medicare bills will diverge sharply. A hidden enrollment deadline, likely missed years ago, may decide who pays and who doesn't.
Asset One Wealth Management LLC boosted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 55.2% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,416 shares of the company's stock after buying an additional 3,706 shares during the period. Asset
MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.
Compass Financial Management LLC lifted its position in shares of Merck and Co., Inc. (NYSE: MRK) by 256.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,733 shares of the company's stock after purchasing an additional 7,001 shares during the quarter.
Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.
Boston Trust Walden Corp cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 12.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 393,390 shares of the company's stock after selling 53,672 shares during the period. Boston Trust Walden
Dow Dogs remain pricey with thin dividends, but 21 of 30 are ‘safer' due to robust free cash flow supporting payouts. Analyst targets project 16.96% to 60.26% net gains for top-ten Dow Dogs by November 2027, though risks and volatility are elevated. None of the top ten Dow Dogs currently meet the ideal dividend-to-price ratio; only Nike achieves 'IDEAL' status but with negative returns and a weak safety margin.
AIA Group Ltd cut its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 12.3% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 394,399 shares of the company's stock after selling 55,326 shares during the quarter.
Aware Super Pty Ltd as trustee of Aware Super boosted its stake in Merck and Co., Inc. (NYSE: MRK) by 15.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,294 shares of the company's stock after acquiring an additional
Merck gets US FDA emergency use nod for treatment of screwworm in dogs
In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything.
Tech stocks keep beating estimates and then selling off anyway, Apple just joined the club, and Wall Street analysts are busy reshuffling their ratings on everything from nuclear energy plays to insurance giants. Here is who got upgraded, downgraded, and initiated today.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care (SOC) with a history of exacerbations. Recruitment of the ENHANCE-3 trial has begun, and the first patients are now enrolli…
The market for GLP-1 drugs is forecast to explode. It may be understated still.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.
International Assets Investment Management LLC raised its position in Merck and Co., Inc. (NYSE: MRK) by 37.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,000 shares of the company's stock after buying an additional 9,608 shares
Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #theclamancountdown #moderna #merck #nubarafeyan #afeyan #cancer #cancervaccine #melanoma #cancerresearch #cancertreatment #vaccines #biotech #biotechnology #healthcare #healthnews #medicalresearch #clinicaltrials #fda #fdaapproval #immunotherapy #pharma…
Founders Financial Securities LLC lowered its position in shares of Merck and Co., Inc. (NYSE: MRK) by 17.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,841 shares of the company's stock after selling 3,449 shares during the quarter. Founders Financial